FDA approval of Akynzeo®

The U.S. Food & Drug Administration approves Helsinn's drug Akynzeo®

European Commission (EC) approved Akynzeo® in the European Union

European Commission (EC)  approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin‑based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union. 

Prev Next

September 29, 2015

The prestigious accreditation recognizes Helsinn’s commitment to reducing cancer risk through...

September 10, 2015

Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®) in the UK by Chugai Pharma UK ...

September 09, 2015

Helsinn, a Swiss Group focused on building
quality cancer care, announced today that additio...

September 08, 2015

Anamorelin is a novel ghrelin receptor agonist, in development for the treatment of cancer an...